The pan-Canadian Pharmaceutical Alliance (pCPA) and Cancer Care Ontario have partnered to create a pan-Canadian Oncology Biosimilars Initiative, which aims to ensure appropriate implementation and cost-effective use of therapeutic oncology biosimilars across Canada. In November 2018, the Initiative held a Pan-Canadian Oncology Biosimilars Summit. The Initiative has released a Proceedings Report of the Summit, as well as a pan-Canadian Oncology Biosimilars Initiative Action Plan.
Separately, Health Canada announced that it is collaborating with the Drug Safety and Effectiveness Network on a project studying patients with inflammatory rheumatic diseases and inflammatory bowel disease who are taking biologic drugs, aiming to compare the safety and effectiveness of biosimilar drugs to the reference biologic drug. The protocol for the study can be found here.
Related Publications & Articles
-
Canada’s Drug Agency releases 2025 Watch List highlighting AI technologies in health care
On March 25, 2025, Canada’s Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada...Read More -
Health Canada publishes Guide to the precision regulating authorities under the Food and Drugs Act
In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.Read More -
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More